Physicochemical properties affecting retinal drug/ coumarin-6 delivery from nanocarrier systems via eyedrop administration

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 6, 2010, Pages 3162-3170

  Inokuchi, Yuta ^a   Hironaka, Kohei ^a   Fujisawa, Takuya ^a   Tozuka, Yuichi ^a   Tsuruma, Kazuhiro ^a   Shimazawa, Masamitsu ^a   Takeuchi, Hirofumi ^a   Hara, Hideaki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ESCULIN; EYE DROPS; LIPOSOME; NANOCARRIER; COUMARIN 6; COUMARIN DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; EMULSION; EPIFLUORESCENCE MICROSCOPY; LIPOSOMAL DELIVERY; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RETINA; TISSUE DISTRIBUTION; ZETA POTENTIAL; ANIMAL; DRUG EFFECT; FLUORESCENCE MICROSCOPY; MACACA; RABBIT;

ANIMALS; COUMARINS; DRUG DELIVERY SYSTEMS; EMULSIONS; LIPOSOMES; MACACA FASCICULARIS; MALE; MICE; MICROSCOPY, FLUORESCENCE; OPHTHALMIC SOLUTIONS; PARTICLE SIZE; RABBITS; RETINA; THIAZOLES;

EID: 77953245220     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4697     Document Type: Article

References (33)

1. Eldaly MA, Styles C. First versus second eye intravitreal ranibi-zumab therapy for wet AMD. Retina. 2009;29:325-328.
2. Carneiro A, Falcao M, Pirraco A, Milheiro-Oliveira P, Falcao-Reis F, Soares R. Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells. Exp Eye Res. 2009;88:522-527.
3. Kim H, Robinson SB, Csaky KG. Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina. Pharm Res. 2009;26:329-337.
4. Maurice D. Review: practical issues in intravitreal drug delivery. J Ocul Pharmacol Ther. 2001;17:393-401.
5. Lim JI, Wolitz RA, Dowling AH, Bloom HR, Irvine AR, Schwartz DM. Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol. 1999;127:288-293.
6. Shane TS, Martin DF. Endophthalmitis after ganciclovir implant in patients with AIDS and cytomegalovirus retinitis. Am J Ophthal-mol. 2003;136:649-654.
7. Janoria KG, Gunda S, Boddu SH, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv. 2007;4:371-388.
8. Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008;13:144-151.
9. Law SL, Huang KJ, Chiang CH. Acyclovir-containing liposomes for potential ocular delivery: corneal penetration and absorption. J Control Release. 2000;63:135-140.
10. Hathout RM, Mansour S, Mortada ND, Guinedi AS. Liposomes as an ocular delivery system for acetazolamide: in vitro and in vivo studies. AAPS PharmSciTech. 2007;8:1.
11. Abdelbary G, El-Gendy N. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech. 2008;9:740-747.
12. Agnihotri SM, Vavia PR. Diclofenac-loaded biopolymeric nanosus-pensions for ophthalmic application. Nanomedicine. 2009;5:90-95.
13. Badawi AA, El-Laithy HM, El Qidra RK, El Mofty H, El Dally M. Chitosan based nanocarriers for indomethacin ocular delivery. Arch Pharm Res. 2008;31:1040-1049.
14. Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: an overview. Int J Pharm. 2004;269:1-14.
15. Hironaka K, Inokuchi Y, Tozuka Y, Shimazawa M, Hara H, Takeu-chi H. Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye. J Control Release. 2009; 136:247-253.
16. Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res. 2009;26:1197-1216.
17. Shimazawa M, Inokuchi Y, Ito Y, et al. Involvement of ER stress in retinal cell death. Mol Vis. 2007;13:578-587.
18. Yoncheva K, Lizarraga E, Irache JM. Pegylated nanoparticles based on poly(methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive properties. Eur J Pharm Sci. 2005; 24:411-419.
19. Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm. 2007;340:126-133.
20. Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis. 2008; 14:150-160.
21. Amrite AC, Kompella UB. Size-dependent disposition of nanopar-ticles and microparticles following subconjunctival administration. J Pharm Pharmacol. 2005;57:1555-1563.
22. Mainardes RM, Urban MC, Cinto PO, et al. Colloidal carriers for ophthalmic drug delivery. Curr Drug Targets. 2005;6:363-371.
23. Vandamme TF. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res. 2002;21:15-34.
24. Marti-Mestres G, Nielloud F. Emulsions in health care applications. J Dispersion Sci Technol. 2002;23:419-439.
25. Naveh N, Muchtar S, Benita S. Pilocarpine incorporated into a submicron emulsion vehicle causes an unexpectedly prolonged ocular hypotensive effect in rabbits. J Ocul Pharmacol. 1994;10: 509-520.
26. Calvo P, Alonso MJ, Vila-Jato JL, Robinson JR. Improved ocular bioavailability of indomethacin by novel ocular drug carriers. J Pharm Pharmacol. 1996;48:1147-1152.
27. Utsumi H, Inoue K, Nojima S, Kwan T. Motional state of spinlabeled stearates in lecithin-cholesterol liposomes and their incorporation capability. Chem Pharm Bull. 1974;24:1219-1225.
28. Nakano K, Tozuka Y, Yamamoto H, Kawashima Y, Takeuchi H. A novel method for measuring rigidity of submicron-size lipo-somes with atomic force microscopy. Int J Pharm. 2008;355: 203-209.
29. Schulz D, Iliev ME, Frueh BE, Goldblum D. In vivo pachymetry in normal eyes of rats, mice and rabbits with the optical low coherence reflectometer. Vision Res. 2003;43:723-728.
30. Scheppke L, Aguilar E, Gariano RF, et al. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J Clin Invest. 2008;118:2337-2346.
31. Amrite AC, Edelhauser HF, Kompella UB. Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Invest Ophthalmol Vis Sci. 2008;49:320-332.
32. Hughes PM, Olejnik O, Chang-Lin JE, Wilson CG. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev. 2005;57:2010-2032.
33. Kim ES, Durairaj C, Kadam RS, et al. Human scleral diffusion of anticancer drugs from solution and nanoparticle formulation. Pharm Res. 2009;26:1155-1161.